Biogen vs Exelixis
Biogen (BIIB) and Exelixis (EXEL) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $36.9B
- Last close
- $249.59
- 12 months
- +48.4%
- Market value
- $15.8B
- Last close
- $64.63
- 12 months
- +54.7%
At a glance
- The biggest part of Biogen's revenue is TYSABRI (17%); at Exelixis it is CABOMETYX (91%).
- By market value, Biogen ($36.9B) is about 2.3 times Exelixis ($15.8B).
- Over the last 12 months Biogen's share price moved +48.4% and Exelixis's +54.7%; against the S&P 500 that is +42.7 points and +49.0 points.
- In their last fiscal years Biogen kept 13.1% of revenue as net income and Exelixis 33.7%.
- In the last 90 days insiders reported 0 open-market purchases at Biogen and 0 at Exelixis; members of Congress disclosed 2 trades in Biogen and 0 in Exelixis.
- Next results: Biogen Feb 4, 2027, Exelixis Feb 8, 2027.
How each one makes money: Biogen revenue · Exelixis revenue
Share prices on one chart
Biogen and Exelixis, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Biogen BIIBNASDAQ · Biotechnology | Exelixis EXELNASDAQ · Biotechnology | |
|---|---|---|
| Size and profitability | ||
| Market value | $36.9B | $15.8B |
| Revenue, last fiscal year | $9.89B | $2.32B |
| Net income, last fiscal year | $1.29B | $783M |
| Net marginNet income as a share of revenue | 13.1% | 33.7% |
| Free cash flow | $2.05B | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Biogen against
Common questions
How is Biogen different from Exelixis?
Biogen (BIIB) is in Biotechnology on NASDAQ, with $9.89B of revenue in its last fiscal year and a net margin of 13.1%. Exelixis (EXEL) is in Biotechnology on NASDAQ, with $2.32B of revenue in its last fiscal year and a net margin of 33.7%. The biggest part of Biogen's revenue is TYSABRI (17%); at Exelixis it is CABOMETYX (91%). The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Biogen and Exelixis compare in size?
Biogen has the larger market value: Biogen $36.9B and Exelixis $15.8B, at the last close.
Whose share price rose more over the last 12 months, BIIB or EXEL?
Over the last 12 months Biogen moved +48.4% and Exelixis +54.7%. Past price moves say nothing about the future.
Which has had more insider buying, Biogen or Exelixis?
Since 2006, Exelixis insiders reported 114 open-market purchases against 34 for Biogen. These are counts of what was filed, not a view on either stock.
Do members of Congress trade BIIB or EXEL?
In the last 12 months, members of Congress disclosed 9 trades in Biogen (BIIB) and 0 in Exelixis (EXEL).
When did insiders last buy BIIB and EXEL?
Biogen: Feb 18, 2026. Exelixis: Nov 26, 2025.
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Biogen pageExelixis pageRare insider trades this weekAll comparisons
https://oqro.io/compare/biib-vs-exel







